这种脯氨酸特异性寡肽酶是利用转基因黑曲霉自克隆株产生的脯氨酸寡肽酶制剂。欧盟食品安全局专家组对这种脯氨酸特异性寡肽酶的安全性进行了评估。专家组经过评估认为，脯氨酸特异性寡肽酶无遗传毒性。它的目标使用人群为一般成年人，预期最大使用量为每?746 mg TOS/人或39.2 mg TOS/kg 体重（默认一般成年人的体重为70KG）、/div>
[
食品资讯搜索] [
加入收藏] [
告诉好友] [
打印本文] [
关闭窗口]
部分原文报道如下９/div>
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies （NDA was asked to deliver an opinion on proline-specific oligopeptidase （Tolerase G as a novel food ingredient submitted pursuant to Regulation （EC No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel co
nsiders that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy co
nsumption by these animals. Taking into account the intended maximum use level for Tolerase G, its daily co
nsumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight （bw per day, when co
nsidering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel co
nsiders that it is unlikely that such effects would occur in human at the intended use levels. The Panel co
ncludes that the NF, Tolerase G, is safe for the intended use at the intended use level.
原文链接９/div>
http://www.efsa.europa.eu/en/efsajournal/pub/4681
相关政策解读
日期９a href="//www.sqrdapp.com/news/2017-02-20.html">2017-02-20
地区９/font>
| ? 欧盟食品安全局发布2022年欧盟食品中农药残留?/a> |
行业相关食品资讯
地区相关食品资讯
|
欧盟评估转基因玉米MO
欧盟评估一种麦芽糖淀
美国拟撤销若干肉类叉/a>
鲁公网安 37060202000128叶/a>
